Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131795) titled 'Adjuvant hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab in reducing the risk of recurrence in high-risk patients after hepatic cancer resection: a single-center, single-arm, perspective, phase II study' on Sept. 7.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Hepatocellular carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-07
Target Sample Size: Experimental group:60;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html...